AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02969837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22
Study NCT00059852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00059852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02499666 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
Study NCT04110288 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease
Study NCT04110288 — intervention group
Intervention type: DEVICE
Intervention: Non-drug coated Device Treatment
Study NCT02838394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Acupuncture filiform needles are inserted into myofascial trigger points
Study NCT02838394 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: Blunted needles will be pressed against the skin, but no actual penetration will occur
Study NCT02499666 — intervention group
Intervention type: DEVICE
Intervention: Coronary stent
Description: As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
Study NCT02499666 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
Study NCT00925626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-Vastus arthrotomy
Description: Sub-vastus arthrotomy
Study NCT00925626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid - Vastus arthrotomy
Description: Mid-vastus arthrotomy
Study NCT03542422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
Study NCT04249973 — intervention group
Intervention type: OTHER
Intervention: Collection of urine and feces
Description: Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
Study NCT03145870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echoing of the lower limbs and measuring the systolic pressure index
Description: Echoing of the lower limbs and measuring the systolic pressure index
Study NCT03320577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Class instruction of breathing exercises
Description: Pranayama Breathing exercises practiced at least 5 times a week and log practice times
Study NCT03320577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD instruction of breathing exercises
Description: Pranayama Breathing exercises practiced at least 5 times a week and log practice times
Study NCT01828996 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shock wave therapy
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
Study NCT03320577 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Log dinner times
Study NCT04396561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral group (group P):
Description: In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels.
Study NCT01828996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave therapy
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
Study NCT01828996 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
Study NCT01828996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
Study NCT02923947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib; AZD9291
Description: 80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
Study NCT01064349 — intervention group
Intervention type: DRUG
Intervention: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
Description: Trastuzumab or Lapatinib
Study NCT02200965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes, My Information, My Plan Document
Description: A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
Study NCT04047095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrients + normal daily meal
Description: Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g).
Study NCT04047095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal daily meal
Description: Normal daily meal (75-80 g protein)
Study NCT03062566 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
Study NCT04526496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTP-198, single dose
Description: Single dose of FTP-198, 6 dose levels, oral suspension
Study NCT04526496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, single dose
Description: Placebo matched to FTP-198, oral suspension
Study NCT04526496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTP-198, multiple doses
Description: Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
Study NCT04526496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, multiple doses
Description: Placebo matched to FTP-198, oral suspension, 7 days
Study NCT03778905 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
Study NCT04646109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions.
Study NCT02892500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine hydrochloride and betamethasone sodium phosphate
Description: 5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
Study NCT02892500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine hydrochloride
Description: 5ml of bupivacaine hydrochloride into the tibiofibular ligament
Study NCT03855475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
Study NCT03855475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will complete 12 weeks of supervised stretching, 3 times per week
Study NCT01743378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block Ropivacaine 0,75 %
Study NCT01743378 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block Saline 0,9 %
Study NCT05520788 — intervention group
Intervention type: GENETIC
Intervention: precise medicine
Description: During screening stage, all patients should accept next-generation sequencing (NGS) test.
Study NCT01171690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
Study NCT03571048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Calorie Diet (RCD)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
Study NCT03571048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet (RCD)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
Study NCT03571048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
Study NCT00592098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate
Description: Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
Study NCT00592098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
Study NCT03673488 — intervention group
Intervention type: DEVICE
Intervention: TephaFlex™ mid-urethral sling
Description: The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
Study NCT04281563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with MCT oil (group 1)
Description: Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
Study NCT04281563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with MCT oil (group 1)
Description: Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
Study NCT02107300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeutraSal
Description: NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
Study NCT02107300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
Study NCT04522609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session.
Study NCT04448678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Education Program (HIEP)
Description: \[See arm/group descriptions\]
Study NCT04448678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: \[See arm/group descriptions\]
Study NCT06389409 — intervention group
Intervention type: OTHER
Intervention: Observation of testicular cancer patients
Description: Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
Study NCT03361228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
Study NCT03361228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat at the protocol-defined dose administered orally twice daily.
Study NCT03361228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
Study NCT00302952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Study NCT00302952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Study NCT02136095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography (IFC)
Description: A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
Study NCT05455073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly Iron and Folic Acid Supplementation (WIFA)
Description: Weekly school provision of WIFA tablets to adolescent girls
Study NCT05455073 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: WASH
Description: Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
Study NCT05455073 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menstrual Hygiene Management
Description: Support for adolescent girls' menstrual hygiene
Study NCT05455073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Behavior Change Intervention (BCI)
Description: Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
Study NCT05455073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MHM & WASH Behavior Change Intervention (BCI)
Description: Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
Study NCT01936948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clip closure
Description: Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
Study NCT02365207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG strain of Mycobacterium bovis
Description: Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Study NCT01092351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: 100 mg retard capsules to be taken twice daily for seven days
Study NCT02582541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS alone
Description: The SEMS (Wallstent, Boston Scientific, USA) would be placed.
Study NCT02582541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SEMS plus radiofrequency ablation
Description: The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
Study NCT01988922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.4 mg/kg oral racemic ketamine
Study NCT02968186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation program
Description: Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
Study NCT03432845 — intervention group
Intervention type: OTHER
Intervention: compare reversal agents
Description: compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
Study NCT03116386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: run-in period
Description: observational time i.e. baseline situation
Study NCT03116386 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control period
Description: neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
Study NCT03116386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etolya-F ® devices
Description: Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
Study NCT01674556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Gemcitabine in combination with ultrasound (US) contrast agent under sonication